Lungs News and Research

RSS

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.

10 Feb 2010

Biovail and Alexza Pharmaceuticals sign collaboration and license agreement for anti-agitation drug

Biovail Corporation today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into a collaboration and license agreement with Alexza Pharmaceuticals, Inc.

10 Feb 2010

Researchers find differences in the biology of lung cancer between men and women

An analysis of genetic and clinical data for nearly 800 patients with non-small cell lung cancer has identified differences in genetic characteristics that are associated with age and sex specific patterns of increased or decreased recurrence-free survival, according to a study in the February 10 issue of JAMA.

10 Feb 2010

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.

10 Feb 2010

People living with IBD are at high risk of blood clots

People living with Inflammatory Bowel Disease (IBD) are known to be at high risk of blood clots when admitted to hospital during a flare-up of their disease but now new research by scientists at The University of Nottingham has shown that those who are not admitted to hospital during flare-ups are also at risk.

10 Feb 2010

Biology of lung cancer varies by age and gender

The biology of lung cancer differs from one patient to the next, depending on age and sex, according to scientists at Duke University Medical Center. The findings may help explain why certain groups of patients do better than others, even though they appear to have the same disease.

10 Feb 2010

Low potassium levels increase risk of death in patients with heart failure and CKD

New research from the University of Alabama at Birmingham (UAB) says low potassium levels produce an increased risk of death or hospitalization in patients with heart failure and chronic kidney disease (CKD).

10 Feb 2010

Researchers find that mutation in single gene can cause endometrial cancer

A mutation in a single gene can cause endometrial cancer that is responsive to a specific drug therapy, researchers at UT Southwestern Medical Center have found in an animal study.

10 Feb 2010

UnitedHealthcare launches OCA program for cancer patients

UnitedHealthcare, a UnitedHealth Group (NYSE: UNH) company, launched its Oncology Care Analysis (OCA) program. This patient-focused, integrated program uses a first-of-its-kind database that combines clinical and claims data to gauge the quality of cancer patient care based on approved treatment guidelines from the National Comprehensive Cancer Network (NCCN), an alliance of 21 leading cancer centers.

10 Feb 2010

Report shows 3.4% of adult Minnesotans suffer from COPD

The nation's fourth leading cause of death, chronic obstructive pulmonary disease (COPD), is now being measured by the Minnesota Department of Health's Environmental Public Health Tracking Program. The program focuses on three major causes of hospitalizations in Minnesota that can be triggered or made worse by environmental factors such as secondhand smoke or outdoor air pollution — asthma, heart attacks and COPD.

10 Feb 2010

TBTC to receive more than $90 million to develop effective tuberculosis treatments

The Tuberculosis Trials Consortium (TBTC) strives to conduct research about the diagnosis, medical treatment, and prevention of tuberculosis (TB) infection and disease. The network is composed of a partnership of clinical investigators from the U.S. Centers for Disease Control and Prevention (CDC), public health departments from different countries, as well as medical and pharmaceutical institutions.

10 Feb 2010

Mutations that enable Pseudomonas to thrive in cystic fibrosis lung secretions may also guard them against antibiotics

People with cystic fibrosis, an inherited disease that clogs airways with thick mucous, frequently have lung infections that defy treatment. While the life expectancy for children with cystic fibrosis has increased over the past few decades, many lives are still shortened in young adulthood by the ravages of lung infections.

10 Feb 2010

Insurer to take new role in assessing cancer treatments

UnitedHealthcare, one of the nation's biggest insurance companies, has decided to take a more active role in the care of its policy holders who are being treated for several types of cancer, The Wall Street Journal reports.

9 Feb 2010

Leading researchers discuss latest breakthroughs and best forms of cancer prevention

Eating a balanced diet and preparing your food in the correct way may be your best defense against developing cancer, according to top cancer researchers

9 Feb 2010

Low potassium levels increase risk of death in patients with heart failure and CKD

9 Feb 2010

NNK induces epigenetic alteration during cancer formation and inhibits tumor suppressor genes

In the history of humans fighting against cancer, the relationship between tobaccos and cancer has been an important subject for the academic and clinical research. By understanding the mechanism of why cancer is caused by tobaccos, scientists around the world all anticipate to solve the mystery of cancer and find the way of prevention and cure.

9 Feb 2010

QIAGEN acquires global licence for PI3K gene to develop real-time-PCR and endpoint PCR assays

QIAGEN today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays.

From QIAGEN Manchester Limited 8 Feb 2010

Over 12,000 courses of lung cancer treatment completed with Accuray's CyberKnife radiosurgery

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that more than 12,000 courses of lung cancer treatment have been completed with CyberKnife radiosurgery. Usage of CyberKnife radiosurgery for lung cancer continues to grow, as illustrated by a 25 percent increase year over year in calendar year 2009.

6 Feb 2010

FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficiency

Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled treatments available for the treatment of AAT deficiency.

5 Feb 2010

Lungs News and Research

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

Biovail and Alexza Pharmaceuticals sign collaboration and license agreement for anti-agitation drug

Researchers find differences in the biology of lung cancer between men and women

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

People living with IBD are at high risk of blood clots

Biology of lung cancer varies by age and gender

Low potassium levels increase risk of death in patients with heart failure and CKD

Researchers find that mutation in single gene can cause endometrial cancer

UnitedHealthcare launches OCA program for cancer patients

Report shows 3.4% of adult Minnesotans suffer from COPD

TBTC to receive more than $90 million to develop effective tuberculosis treatments

Mutations that enable Pseudomonas to thrive in cystic fibrosis lung secretions may also guard them against antibiotics

Insurer to take new role in assessing cancer treatments

Leading researchers discuss latest breakthroughs and best forms of cancer prevention

Low potassium levels increase risk of death in patients with heart failure and CKD

NNK induces epigenetic alteration during cancer formation and inhibits tumor suppressor genes

QIAGEN acquires global licence for PI3K gene to develop real-time-PCR and endpoint PCR assays

Over 12,000 courses of lung cancer treatment completed with Accuray's CyberKnife radiosurgery

FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficiency

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News